Syd985 treatment of t-dm1 refractory cancer patients

Abstract

The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+ / FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the treatment of trastuzumab emtansine (T-DM1) refractory cancer patients, particularly T-DM1 refractory breast cancer patients.BACKGROUND OF THE PRESENT INVENTION[0002]Antibodies have been conjugated to a variety of cytotoxic drugs, including small molecules that bind DNA (e.g. anthracyclines), alkylate or crosslink DNA (e.g. duocarmycins and pyrrolobenzodiazepine dimers, respectively), cause DNA strand breaks (e.g. calicheamicins) or disrupt microtubules (e.g. maytansinoids, auristatins, and tubulysins). These combined molecules are referred to as antibody-drug conjugates (ADCs).[0003]Duocarmycins, first isolated from a culture broth of Streptomyces species, are members of a family of antitumor antibiotics that include duocarmycin A, duocarmycin SA, and CC-1065. Duocarmycins bind to the minor groove of DNA and subsequently cause irreversible alkylation of DNA. This disrupts the nucleic acid architecture, which eventually...

AI Technical Summary

Benefits of technology

The patent text explains that it's possible to treat patients who no longer respond to trastuzumab conjugated to a DM1 payload with another trastuzumab conjugated to a duocarmycin payload. This is surprising because both conjugates use the same antibody to deliver the payload. The technical effect of this is that it expands the treatment options for patients who have developed resistance to certain drugs.

Problems solved by technology

This disrupts the nucleic acid architecture, which eventually leads to tumor cell death.

Despite the improvement over trastuzumab for the treatment of HER2-positive (metastatic) breast cancer by the introduction of T-DM1 in clinical practice, T-DM1 can cause severe problems of heart, liver and lung with additional possible serious infusion related reactions, bleeding, low platelet count, nerve damage and skin reactions around the infusion site.

Consequently, treatment with T-DM1 may have to be discontinued because of (unacceptable) toxicity.

Furthermore, cancer patients, particularly (metastatic) breast cancer patients, may become refractory to T-DM1 treatment, meaning that after an initial positive response to T-DM1 such treatment is discontinued because of disease progression.

Images